Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin.
BACKGROUND
Renal dysfunction early after kidney transplantation has multiple causes including ischemia-reperfusion (I/R) injury and drug-induced nephrotoxicity. This study assesses the acute nephrotoxicity of tacrolimus (Tac) and sirolimus (Sir) in a rat renal isograft model.


METHODS
Lewis renal isografts and uninephrectomized rats that did not undergo transplantation were treated with various doses of Tac (0.5-5.0 mg/kg/d) or Sir (0.5-6.5 mg/kg/d). Kidneys were examined on day 14 by routine histology and immunohistochemistry for transforming growth factor (TGF)-beta1 and alpha-smooth muscle actin (SMA).


RESULTS
Both Tac and Sir demonstrated evidence of nephrotoxicity in the early posttransplant period including increased serum creatinine and morphologic changes in the graft including interstitial inflammation, fibrosis, and tubular vacuolization. Nephrotoxicity was most prominent in the high-dose treatment groups for both drugs and was more severe in transplanted kidneys than in uninephrectomized animals that did not undergo transplantation, suggesting an additive effect of I/R injury and drug nephrotoxicity. Both Tac and Sir increased intragraft TGF-beta1 and alpha-SMA, but there were distinct differences in the patterns of TGF-beta1 expression. Both demonstrated TGF-beta1 in tubular epithelial cells, but Sir was associated with proximal tubular TGF-beta1 localization in a bright granular pattern, whereas Tac was associated with diffuse distal tubular staining.


CONCLUSIONS
Both Tac and Sir may be nephrotoxic in the early posttransplant period, especially at high doses and when combined with I/R injury. Immunohistochemical localization of TGF-beta1 in the tubular cells was distinctly different with each drug, suggesting possible differences in the mechanism(s) of nephrotoxicity requiring further study.
Ninova
Dora
D
Department of Surgery, Division of Transplant Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Covarrubias
Marco
M
Rea
David J
DJ
Park
Walter D
WD
Grande
Joseph P
JP
Stegall
Mark D
MD
D000199:Actins / Q000235:genetics*; D000818:Animals; D003404:Creatinine / Q000097:blood; D005786:Gene Expression Regulation / Q000276:immunology; D007166:Immunosuppressive Agents / Q000633:toxicity; D007249:Inflammation; D007668:Kidney / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D007684:Kidney Tubules / Q000473:pathology; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D020123:Sirolimus / Q000633:toxicity*; D016559:Tacrolimus / Q000633:toxicity*; D016212:Transforming Growth Factor beta / Q000235:genetics*; D053773:Transforming Growth Factor beta1; D014185:Transplantation, Isogeneic
D000199:Actins; D007166:Immunosuppressive Agents; C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D003404:Creatinine; D020123:Sirolimus; D016559:Tacrolimus